Cancers (Apr 2022)

Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer

  • Juan Morote,
  • Angel Borque-Fernando,
  • Marina Triquell,
  • Anna Celma,
  • Lucas Regis,
  • Richard Mast,
  • Inés M. de Torres,
  • María E. Semidey,
  • Anna Santamaría,
  • Jacques Planas,
  • Luis M. Esteban,
  • Enrique Trilla

DOI
https://doi.org/10.3390/cancers14071828
Journal volume & issue
Vol. 14, no. 7
p. 1828

Abstract

Read online

We sought to find further evidence showing the increase in PCa aggressiveness as PI-RADS score increases from four surrogates of PCa aggressiveness: i. prostate biopsy GG (≤3 vs. >3), ii. type of pathology in surgical specimens (favourable vs. unfavourable), iii. clinical stage (localised vs. advanced), and risk of recurrence of localised PCa after primary treatment (low-intermediate vs. high). A group of 692 PCa patients were diagnosed after 3-T multiparametric MRI (mpMRI) and guided and/or systematic biopsies, showing csPCa (GG ≥ 2) in 547 patients (79%) and insignificant PCa (iPCa) in 145 (21%). The csPCa rate increased from 32.4% in PI-RADS p 3 (p 3 (p = 0.030). Advanced disease was not observed in PCa with PI-RADS ≤ 3, while it existed in 12.7% of those with PI-RADS > 3 (p 3 (p = 0.001). The PI-RADS score was an independent predictor of all surrogates of PCa aggressiveness as PSA density. We confirmed that mpMRI grades PCa aggressiveness.

Keywords